ArcaScience Raises €6.5M to Transform Drug Development with AI-Powered Benefit-Risk Intelligence
The round was led by The Moon Venture, with participation from Pléiade Venture, Plug and Play Ventures, Bpifrance, and AKKA Technologies.
This marks ArcaScience’s first institutional funding round, following a €1.3 million pre-seed raise with Plug and Play Ventures and angel investors. The new funds will support the company’s expansion into the US and UK, the launch of its first patient-facing solution (initially focused on paediatric brain cancer and dermatological diseases), and the recruitment of a Chief Medical Officer to accelerate the translation of its AI into measurable clinical impact.
From personal journey to industry transformation
ArcaScience was founded by Romain Clément, who was diagnosed with brain cancer and personally experienced the inefficiencies of treatment design. After his remission, he set out to tackle one of the biggest bottlenecks in drug development: the lack of accurate, patient-centric benefit-risk evaluation.
Today, ArcaScience leverages advanced AI to improve drug assessment for pharmaceutical companies, regulators, clinical teams, and patients.
Scaling AI for better, safer drugs
It takes more than 10 years to bring a drug to market. With a 90% failure rate, the average cost per approved drug is $2.3 billion. Benefit-risk prediction is no longer optional—it’s essential for building better drugs.
This funding will allow us to scale our product and bring real benefit-risk clarity to the pharma industry and patients. We are excited to partner with The Moon Venture, whose founder-investors provide unparalleled access to global healthtech networks, and with Pléiade Venture, who are renowned for helping startups scale sustainably.said Romain Clément, Founder and CEO of ArcaScience.
The global benefit-risk evaluation market is valued at $13 billion annually (Leem, 2023). With AI adoption accelerating in healthcare, experts predict that 80% of pharmaceutical companies will rely on AI solutions for benefit-risk evaluation by 2026.
Growing traction with pharma leaders
ArcaScience already works with 10 global pharma clients, including Sanofi, AstraZeneca, GSK, Takeda, ICON, and the Paris Brain Institute.
The company is also part of a newly formed pan-European consortium focused on applying AI to paediatric brain cancer, created by Sanofi and Imagine for Margo. The consortium brings together institutions such as the Paris Brain Institute, Institut Gustave Roussy, the Medical University of Vienna, AstraZeneca, Roche, and Merck.
Proven impact and recognition
ArcaScience’s platform has already been used by over 70,000 patients in chronic skin disease treatment and is increasingly adopted by clinical operations and pharmacovigilance teams to derisk clinical trials and optimise drug development.
During the COVID-19 crisis, the French government selected ArcaScience to structure and deliver the complete body of scientific knowledge on the virus—demonstrating the robustness and reliability of its platform. The company’s work has been validated in multiple scientific journals.
0 comments